VRDN — Viridian Therapeutics Inc · catalysts, narrative & risks

Snapshot (as of 2026‑10‑27)

Viridian Therapeutics (NASDAQ: VRDN) — a Healthcare/Biotechnology firm — last traded around US$24.09, up ~3.2% on the day, with a market cap of ~US$2.73B and a 52‑week range of US$13.18–US$34.29 [2], [10], [11], [12]. Trailing revenue is ~US$71.1M while the company is still loss‑making (net income ~‑US$334M; EPS TTM roughly ‑US$3.4) [10], [11]. It holds a large cash buffer of ~US$981.5M as of June 30, 2026 [10], [11]. Note that this analysis draws on press releases, equity‑research reports and analyst price targets [LIB‑3], and as with sentiment/news‑driven data these inputs warrant the usual reliability caveats around garbled or stale fields [LIB‑1].

Recent catalysts (last ~1–3 months)